Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine/Melphalan/TBI with Post-Transplant Cyclophosphamide for GVHD Prophylaxis in Allogeneic HSCT
NCT03192397Phase 2Active, not recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Aug 2017
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of melphalan in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and 6 more (5 cohorts), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Cumulative Incidence of Extensive Chronic Graft Versus Host Disease at 1 year. Started Aug 2017; status: active, not recruiting.
02
Drugs
melphalan
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)chronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03192397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03192397.